Laurus Labs share price rose 1 percent in the opening trade on January 23 despite company's foreign subsidiary received one observation from USFDA.
At 09:25am, Laurus Labs was quoting at Rs 579.00, up Rs 7.55, or 1.32 percent, on the BSE.
Laurus Generics Inc. (LGI), a wholly-owned foreign subsidiary of the company at New Jersey, USA underwent a post-marketing adverse drug experience (PADE) inspection by USFDA.
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Laurus Labs marketed products worldwide.
The inspection was conducted between January 13 to 21, 2025 and concluded with a Form 483 with one observation.
The company will address the said observation within stipulated timelines.
Catch all the market action on our live blog
A meeting of the board of directors of the company will be held on Friday, January 24, 2024, to consider and approve the un-audited financial results of the company for the quarter and nine months ended December 31, 2024.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
